Ultrasound and Microbubbles Enhance Uptake of Doxorubicin in Murine Kidneys
Authors:
- Oystein EikremOEOystein Eikrem
- Spiros KotopoulisSKSpiros Kotopoulis
- Mihaela PopaMPMihaela Popa
- Mireia Mayoral SafontMSMireia Mayoral Safont
- Kjell Ove FossanKFKjell Ove Fossan
- Sabine LehSLSabine Leh
- Lea LandoltLLLea Landolt
- Janka BabickovaJBJanka Babickova
- Oddrun Anita GudbrandsenOGOddrun Anita Gudbrandsen
- Odd Helge GiljaOGOdd Helge Gilja
- Bettina RiedelBRBettina Riedel
- Jan SchjøttJSJan Schjøtt
Open Access
- 29 November 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (12) , 2038
Abstract
The use of ultrasound and microbubble-enhanced drug delivery, commonly referred to as sonoporation, has reached numerous clinical trials and has shown favourable results. Nevertheless, the microbubbles and acoustic path also pass through healthy tissues. To date, the majority of studies have focused on the impact to diseased tissues and rarely evaluated the impact on healthy and collateral tissue. The aim of this study was to test the effect and feasibility of low-intensity sonoporation on healthy kidneys in a mouse model. In our work here, we used a clinical diagnostic ultrasound system (GE Vivid E9) with a C1-5 ultrasound transducer combined with a software modification for 20-µs-long pulses to induce the ultrasound-guided drug delivery of doxorubicin (DOX) in mice kidneys in combination with SonoVue® and Sonazoid™ microbubbles. The acoustic output settings were within the commonly used diagnostic ranges. Sonoporation with SonoVue® resulted in a significant decrease in weight vs. DOX alone (p = 0.0004) in the first nine days, whilst all other comparisons were not significant. Ultrasound alone resulted in a 381% increase in DOX uptake vs. DOX alone (p = 0.0004), whilst SonoVue® (p = 0.0001) and Sonazoid™ (p < 0.0001) further increased the uptake nine days after treatment (419% and 493%, respectively). No long-standing damage was observed in the kidneys via histology. In future sonoporation and drug uptake studies, we therefore suggest including an “ultrasound alone” group to verify the actual contribution of the individual components of the procedure on the drug uptake and to perform collateral damage studies to ensure there is no negative impact of low-intensity sonoporation on healthy tissues.Keywords
Funding Information
- Kreftforeningen (6833652)
- Sanofi Genzyme (GZ-2013-11022)
- National Institute of Health (R01CA199646)
This publication has 46 references indexed in Scilit:
- A global pharmaceutical company initiative: An evidence-based approach to define the upper limit of body weight loss in short term toxicity studiesRegulatory Toxicology and Pharmacology, 2013
- Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast CancerPLOS ONE, 2013
- Material characterization of the encapsulation of an ultrasound contrast microbubble and its subharmonic response: Strain-softening interfacial elasticity modelThe Journal of the Acoustical Society of America, 2010
- Design and Evaluation of Doxorubicin-containing Microbubbles for Ultrasound-triggered Doxorubicin Delivery: Cytotoxicity and Mechanisms InvolvedMolecular Therapy, 2010
- Estimating the shell parameters of SonoVue® microbubbles using light scatteringThe Journal of the Acoustical Society of America, 2009
- Inducible rodent models of acquired podocyte diseasesAmerican Journal of Physiology-Renal Physiology, 2009
- How to get genomes at one ten-thousandth the costNature Biotechnology, 2008
- Biomarkers of Acute Kidney InjuryAnnual Review of Pharmacology and Toxicology, 2008
- S-Allylcysteine Ameliorates Doxorubicin Toxicity in the Heart and Liver in MicePlanta Medica, 2000
- Characteristics of SonoVue™Echocardiography, 1999